Propanc Biopharma Files 10-Q for Q2 FY2025

TL;DR

Propanc Biopharma filed its 10-Q for Q2 FY25. Check financials.

AI Summary

Propanc Biopharma, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the second quarter of their fiscal year. Key financial data and operational updates are presented, though specific dollar amounts for revenue, expenses, or cash flow are not detailed in this header information.

Why It Matters

This 10-Q filing provides investors with an update on Propanc Biopharma's financial health and operational progress for the second quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Propanc Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 2024-12-31 — End of Fiscal Year Quarter (Reporting period for the 10-Q)
• 2025-02-14 — Filing Date (Date the 10-Q was submitted to the SEC)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of the reporting period
• 2025-02-14 (date) — Filing date
• 0001517681 (company) — Central Index Key for Propanc Biopharma, Inc.

FAQ

Filing Documents

• form10-q.htm (10-Q) — 2261KB
• ex31-1.htm (EX-31.1) — 9KB
• ex32-1.htm (EX-32.1) — 5KB
• 0001493152-25-006697.txt ( ) — 9063KB
• ppcb-20241231.xsd (EX-101.SCH) — 54KB
• ppcb-20241231_cal.xml (EX-101.CAL) — 61KB
• ppcb-20241231_def.xml (EX-101.DEF) — 256KB
• ppcb-20241231_lab.xml (EX-101.LAB) — 441KB
• ppcb-20241231_pre.xml (EX-101.PRE) — 356KB
• form10-q_htm.xml (XML) — 1417KB

Signatures

Signatures 10 2 PART I — FINANCIAL INFORMATION Item 1. Financial Statements. The following unaudited interim condensed consolidated financial statements of Propanc Biopharma, Inc. are included in this Quarterly Report on Form 10-Q: INDEX TO FINANCIAL STATEMENTS Page Condensed Consolidated Balance Sheets at December 31, 2024 (unaudited) and June 30, 2024 F-2 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended December 31, 2024 and 2023 (unaudited) F-3 Condensed Consolidated Statements of Changes in Stockholders' Deficit for each of the three and six months in the periods ended December 31, 2024 and 2023 (unaudited) F-4 Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2024 and 2023 (unaudited) F-6 Notes to the Condensed Consolidated Financial Statements (unaudited) F-7 F-1 PROPANC BIOPHARMA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS December 31, 2024 June 30, 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 14,633 $ 21,085 GST tax receivable 1,973 2,950 Prepaid expenses and other current assets 1,378 1,406 TOTAL CURRENT ASSETS 17,984 25,441 Deferred offering costs 52,117 27,117 Security deposit - related party 1,855 2,008 Operating lease right-of-use assets, net - related party 6,577 17,799 TOTAL ASSETS $ 78,533 $ 72,365 LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES: Accounts payable $ 1,223,254 $ 1,213,335 Accrued expenses and other payables 899,262 792,190 Accrued interest 135,351 94,612 Loans payable 145,091 145,091 Loans payable - related parties 350,544 71,629 Notes payable, net of discount 168,217 204,694 Convertible notes, net of discounts and including put premiums 409,799 399,325 Operating lease liability - related party, current portion 7,298 19,362 Embedded conversion option liabilities 131,585 133,886 Due to former di

View Full Filing

View this 10-Q filing on SEC EDGAR